基于因子分析的生物制药上市公司成长性评价研究  

Evaluation on growth of listed biopharmaceutical companies based on factor analysis

作　　者：熊佳美 董江萍 XIONG Jia-mei;DONG Jiang-ping(Shenyang Pharmaceutical University,Shenyang 110006.China;Center for Food and Drug Inspection of National Medical Products Administration,Beijing100044.China)

机构地区：[1]沈阳药科大学,沈阳110016 [2]国家药品监督管理局食品药品审核查验中心,北京100044

出　　处：《中国新药杂志》2021年第23期2121-2126,共6页Chinese Journal of New Drugs

摘　　要：本文对我国生物制药上市公司的成长性展开研究。根据申银万国行业分类标准选取36家生物制药上市公司,12项财务指标建立成长性指标评价体系,运用因子分析方法,计算各上市公司成长性综合得分,结果显示,综合得分在0.5以上的公司约占16.7%。整体计算可知,生物制药行业的发展空间较大,我国生物制药上市公司成长性有待提高。结合因子分析结果提出以下建议:精准战略目标,强化主营业务;加强高端人才引进,加大研发经费投入;顺应红利政策,抓住发展机遇。This article studies growth of China’s listed biopharmaceutical companies. According to the Shenyin Wanguo industry classification criteria, 36 biopharmaceutical listed companies were selected, and 12 financial indicators were used to establish a growth index evaluation system. The factor analysis method was used to calculate the comprehensive growth scores of listed companies. The results show that the companies with comprehensive scores above 0.5 account for about 16.7%. The overall calculation result shows that the development space of the biopharmaceutical industry is relatively large, and the growth of China’s biopharmaceutical listed companies still remain to improve. Combined with the results of factor analysis, we make recommendations, such as precise strategic planning and main business strengthening;improving talent introduction, increasing R&D investment;complying beneficial policies, and seizing development opportunities.

关 键 词：生物制药上市公司 成长性 因子分析 

分 类 号：R95[医药卫生—药学]